Pleuromutilin Derivatives Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pleuromutilin derivatives face challenges in metabolic stability, which affects their antimicrobial efficacy and duration of action.
Innovation Solution
Development of novel pleuromutilin compounds with specific structural modifications, including variations in the R, R1, and R2 groups, such as the presence of hydroxy or formyloxy substituents, to enhance metabolic stability and maintain antimicrobial activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pleuromutilin derivatives are developed with various substitutions to enhance antimicrobial activity, then antimicrobial efficacy is improved, but metabolic stability deteriorates
Solution Approach 1:
The patent applies parameter changes by systematically varying the R1, R2, and R3 substituents on the pleuromutilin core structure to optimize the balance between antimicrobial activity and metabolic stability. Specific modifications include introducing hydroxy, formyloxy, or (C1-4)alkylcarbonyloxy groups at R2, and various heterocyclyl or alkyl groups at R3, which alter the compound's metabolic profile while preserving antimicrobial efficacy.
Solution Approach 2:
The patent applies local quality by making specific localized modifications to the pleuromutilin molecule at particular positions (R1, R2, R3 substituents) rather than altering the entire structure. This allows selective enhancement of metabolic stability at certain regions while maintaining the core antimicrobial activity of the pleuromutilin scaffold.
2Duration of action of stationary object
If pleuromutilin derivatives are modified to improve metabolic stability, then duration of action is extended, but antimicrobial activity may be reduced
Solution Approach 1:
The patent uses parameter changes to extend duration of action through specific substituent modifications that enhance metabolic stability. The R2 position modifications (hydroxy, formyloxy, (C1-4)alkylcarbonyloxy) and R3 position modifications (heterocyclyl, alkyl groups) are designed to slow metabolism and prolong half-life while the patent ensures antimicrobial activity is maintained through careful selection of these parameters.
Solution Approach 2:
The patent applies universality by designing a pleuromutilin derivative platform that can simultaneously achieve multiple objectives: maintaining antimicrobial activity against various bacteria while extending duration of action through metabolic stability improvements. The core pleuromutilin structure provides universal antimicrobial activity while the variable substituents provide extended duration of action.
Data Source
AI summary
Compounds of formula (I), which are 14-O-{[(optionally substituted hydroxy)cyclohexyl)sulfanyl]acetyl}mutilins further substituted at the cyclohexyl group by an acylated amino group, salts and solvates thereof, pharmaceutical compositions comprising such compounds and their use as a pharmaceutical, e.g. for the treatment of diseases mediated by microbes and for the treatment of inflammation where microbese are mediating said inflammation.